Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant Cyclophosphamide for GVHD Prevention in Mismatched SCT
NCT01010217Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2009
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, Chronic Myeloid Leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)aplastic anemiaChronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT01010217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010217.